Mangoceuticals Inc (MGRX)

Aug 13, 2026, 4:05 PM EDT - 5 days ago

Nuclea Energy, Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets

Aug 13, 2026, 4:05 PM EDT - 5 days ago

Mangoceuticals Inc.'s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets

Aug 13, 2026, 7:00 AM EDT - 6 days ago

Mangoceuticals Quarterly report: Q2 2026

2026-08-06T13:11:47.000Z - 13 days ago

Mangoceuticals’ partner Nuclea signs MOU with New Mining on reactor

Aug 6, 2026, 7:00 AM EDT - 13 days ago

Nuclea Energy Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure

Aug 6, 2026, 7:00 AM EDT - 13 days ago

Mangoceuticals' Merger Partner, Nuclea Energy Inc., Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure

Aug 5, 2026, 4:05 PM EDT - 13 days ago

Nuclea Energy USA Inc. Announces MOU with Utah Office of Energy Development

Aug 5, 2026, 4:05 PM EDT - 13 days ago

Mangoceuticals' Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development

Aug 4, 2026, 4:05 PM EDT - 14 days ago

Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination

Jul 30, 2026, 10:35 AM EDT - 20 days ago

Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor

2026-07-30T13:27:13.000Z - 20 days ago

Mangoceuticals enters business combination agreement with Nuclea Energy

Jul 30, 2026, 7:00 AM EDT - 20 days ago

Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology

May 19, 2026, 7:00 AM EDT - 3 months ago

Mangoceuticals Quarterly report: Q1 2026

Apr 1, 2026, 7:00 AM EDT - 5 months ago

Mangoceuticals Annual report: Q4 2025

2026-03-23T13:27:03.000Z - 5 months ago

Why Is Mangoceuticals, Inc. Stock (MGRX) Up Today?

2026-03-17T20:15:36.000Z - 5 months ago

Mangoceuticals files civil lawsuit against Clarity Ventures

Mar 17, 2026, 4:00 PM EDT - 5 months ago

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

2026-03-06T21:10:53.000Z - 5 months ago

Mangoceuticals announces patent filing for MGX-0024

Mar 6, 2026, 4:00 PM EST - 5 months ago

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Feb 23, 2026, 4:05 PM EST - 6 months ago

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

2026-02-20T14:09:28.000Z - 6 months ago

Here’s Why Mangoceuticals Stock (MGRX) Rocketed Today

Feb 19, 2026, 4:05 PM EST - 6 months ago

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

Jan 23, 2026, 7:00 AM EST - 7 months ago

Mangoceuticals Registration statement: Registration Filing

2026-01-13T22:35:14.000Z - 7 months ago

Mangoceuticals files to sell 2.64M shares of common stock for holders

Jan 13, 2026, 7:00 AM EST - 7 months ago

Mangoceuticals Registration statement: Registration Filing

Dec 19, 2025, 10:38 AM EST - 8 months ago

Mangoceuticals, Inc. Announces Closing of $2.5 Million Registered Direct and Private Placements

2025-12-19T12:35:43.000Z - 8 months ago

Mangoceuticals, Cube Group partner for up to $100M Solana-focused DAT strategy

Dec 19, 2025, 7:30 AM EST - 8 months ago

Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy

2025-12-18T13:41:44.000Z - 8 months ago

Mangoceuticals announces $2.5M registered direct, private placements

Dec 18, 2025, 8:30 AM EST - 8 months ago

Mangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq Rules

Nov 14, 2025, 4:00 PM EST - 9 months ago

Mangoceuticals Quarterly report: Q3 2025

2025-11-14T10:17:04.000Z - 9 months ago

Investors Flee Mangoceuticals Stock (MGRX) after Eli Lilly and Novo Nordisk Deny Partnership

LLY NVO

Nov 13, 2025, 7:37 PM EST - 9 months ago

Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs

2025-11-13T19:35:28.000Z - 9 months ago

Novo denies partnership with Mangoceuticals on obesity drug, Reuters says

LLY NVO

2025-11-13T19:30:24.000Z - 9 months ago

Eli Lilly says ‘no affiliation’ with Mangoceuticals

LLY NVO

Nov 13, 2025, 2:04 PM EST - 9 months ago

Novo Nordisk, Lilly deny partnership with Mangoceuticals on obesity drugs

LLY NVO

2025-11-13T14:10:42.000Z - 9 months ago

Mangoceuticals Stock (MGRX) Soars on Deal to Sell Obesity Drugs for Eli Lilly, Novo Nordisk

AZN LLY MTSR NVO PFE

2025-11-13T12:25:27.000Z - 9 months ago

Mangoceuticals partner with Eli Lilly, Novo, provide access to Zepbound, Wegovy

LLY NVO

Nov 13, 2025, 7:15 AM EST - 9 months ago

Mangoceuticals partners with Lilly, Novo Nordisk to sell weight-loss drugs

LLY NVO

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Mangoceuticals Quarterly report: Q2 2025

2025-06-13T20:35:18.000Z - 1 year ago

Mangoceuticals files $150M mixed securities shelf

Jun 13, 2025, 8:00 AM EDT - 1 year ago

Mangoceuticals Registration statement: Registration Filing

2025-05-30T20:35:11.000Z - 1 year ago

Mangoceuticals files to sell 4.46M shares of common stock for holders

May 30, 2025, 8:00 AM EDT - 1 year ago

Mangoceuticals Registration statement: Registration Filing

2025-05-27T13:15:43.000Z - 1 year ago

Mangoceuticals shares results from field studies on MGX-0024

May 27, 2025, 9:00 AM EDT - 1 year ago

Mangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu

May 15, 2025, 12:00 AM EDT - 1 year ago

Mangoceuticals Quarterly report: Q1 2025

Apr 28, 2025, 9:36 AM EDT - 1 year ago

ArcStone Securities and Investments Corp. Publishes Industry Report on The Rapid Expansion of The Oral Stimulant Pouch Market

Apr 26, 2025, 10:54 AM EDT - 1 year ago

CORRECTION FROM SOURCE: ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of IP Assets of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector

Apr 25, 2025, 10:26 AM EDT - 1 year ago

ArcStone Securities and Investments Corp. Serves as Exclusive Financial Advisor to Mangoceuticals Inc. (MGRX) on its Transformative Acquisition of Smokeless Technology Corp. Marking its Entry into the High Growth Oral Stimulant Pouch Sector

Apr 25, 2025, 9:00 AM EDT - 1 year ago

Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

Apr 22, 2025, 1:55 PM EDT - 1 year ago

CEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health Landscape

Mar 19, 2025, 7:00 PM EDT - 1 year ago

Mangoceuticals Annual report: Q4 2024

Feb 18, 2025, 7:00 AM EST - 1 year ago

Mangoceuticals Proxy statement: Proxy Filing

Feb 6, 2025, 7:00 AM EST - 1 year ago

Mangoceuticals Proxy statement: Proxy Filing

Feb 3, 2025, 8:30 AM EST - 1 year ago

Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

Dec 19, 2024, 5:33 PM EST - 1 year ago

Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

Nov 14, 2024, 4:00 PM EST - 1 year ago

Mangoceuticals Quarterly report: Q3 2024

Oct 21, 2024, 5:10 PM EDT - 1 year ago

MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly

Oct 18, 2024, 8:45 AM EDT - 1 year ago

Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024

Oct 11, 2024, 5:15 PM EDT - 2 years ago

MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN

Oct 3, 2024, 8:30 AM EDT - 2 years ago

MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions

Oct 1, 2024, 7:30 AM EDT - 2 years ago

MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment

Aug 16, 2024, 8:00 AM EDT - 2 years ago

Mangoceuticals Registration statement: Registration Filing

Aug 15, 2024, 9:25 AM EDT - 2 years ago

MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024

Aug 15, 2024, 7:00 AM EDT - 2 years ago

Mangoceuticals Quarterly report: Q2 2024

Aug 15, 2024, 7:00 AM EDT - 2 years ago

Mangoceuticals Earnings release: Q2 2024

Aug 9, 2024, 8:15 AM EDT - 2 years ago

MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide

Aug 8, 2024, 8:30 AM EDT - 2 years ago

MangoRx Receives Request for Proposal (RFP) From ISFLST for New Male Enhancement Product Exclusive for the Asian Market

Jul 24, 2024, 8:15 AM EDT - 2 years ago

MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology

Jul 18, 2024, 4:05 PM EDT - 2 years ago

Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access

Jul 16, 2024, 8:20 AM EDT - 2 years ago

MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts

Jul 12, 2024, 1:30 PM EDT - 2 years ago

MangoRx Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department

Jul 11, 2024, 8:15 AM EDT - 2 years ago

MangoRx Announces Strategic Partnership for Expansion into Asia Pacific and Key Emerging Markets

Jun 6, 2024, 8:30 AM EDT - 2 years ago

MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology

Jun 4, 2024, 4:00 PM EDT - 2 years ago

MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies

May 28, 2024, 8:30 AM EDT - 2 years ago

Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American Markets

May 23, 2024, 8:30 AM EDT - 2 years ago

MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts

May 21, 2024, 8:30 AM EDT - 2 years ago

MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 Medications

May 16, 2024, 4:40 PM EDT - 2 years ago

MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration

May 16, 2024, 8:00 AM EDT - 2 years ago

Mangoceuticals Proxy statement: Proxy Filing

May 15, 2024, 6:00 PM EDT - 2 years ago

Mangoceuticals Quarterly report: Q1 2024

May 6, 2024, 8:00 AM EDT - 2 years ago

Mangoceuticals Registration statement: Registration Filing

May 6, 2024, 8:00 AM EDT - 2 years ago

Mangoceuticals Proxy statement: Proxy Filing

May 2, 2024, 8:00 AM EDT - 2 years ago

Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Mangoceuticals Registration statement: Registration Filing

Apr 12, 2024, 8:45 AM EDT - 2 years ago

Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) Products

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Mangoceuticals Annual report: Q4 2023

Mar 12, 2024, 9:00 AM EDT - 2 years ago

MangoRx Officially Launches ‘PRIME' by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment